MISRA TUSHAR 4
4 · Mersana Therapeutics, Inc. · Filed Aug 18, 2022
Insider Transaction Report
Form 4
MISRA TUSHAR
Chief Manufacturing Officer
Transactions
- Exercise/Conversion
Restricted stock unit
2022-08-16−6,250→ 18,750 total→ Common Stock (6,250 underlying) - Exercise/Conversion
Common Stock
2022-08-16+6,250→ 6,250 total - Sale
Common Stock
2022-08-17$7.10/sh−1,879$13,341→ 4,371 total
Footnotes (5)
- [F1]Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on August 16, 2021.
- [F2]Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs.
- [F3]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.10 to $7.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- [F5]The restricted stock units will vest in equal annual installments over the first four years after the vesting commencement date, August 16, 2021, subject to the Reporting Person's continued service to the Issuer on such vesting date.